Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Analysts predict peak annual sales of around $2.5 billion for Dupixent, which the FDA approved in March last year for eczema – known medically as moderate-to-severe atopic dermatitis – after ...

A TEEN boy's face suddenly began burning and his spot-covered skin peeled away after a filler injection went disastrously ... until something triggers it. Before getting FDA approved fillers ...

Rhodes gave drug injections before and after each encounter. “This arrangement meant that the more prostitution dates the women completed, the more drugs they received,” records show.

At that time Sanofi was cruising towards an important FDA approval for its Dupixent (dupilumab) injection for the skin ... But three years after buying Ziarco for an undisclosed sum, Novartis ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

One patient has reportedly lost vision in one of her eyes after a visit to a ‘fake ... One reads: ‘Lip augmentation is a safe procedure with hyaluronic acid, which moisturises and increases ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...